Pace mate is a technology company.
Pace mate has raised $8.0M across 1 funding round.
Pace mate has raised $8.0M in total across 1 funding round.
Pace mate has raised $8.0M in total across 1 funding round.
Pace mate's investors include Ballast Point Ventures.
PaceMate is a healthcare technology company specializing in cardiac rhythm management software and remote patient monitoring. Its flagship product, PaceMateLIVE, is a cloud-native platform that aggregates data from implantable cardiac devices, ambulatory monitors, consumer ECGs, heart failure products, and EHR systems, enabling electrophysiologists, device clinics, and healthcare systems to manage patient populations efficiently.[1][2][3][5] The platform serves physicians, administrators, clinic staff, and IT teams by streamlining workflows, prioritizing patients via auto-triage, ensuring interoperability with systems like Epic and Cerner, and improving outcomes, reimbursements, and productivity.[1][3][5] Recognized as a Top 100 Healthcare Technology Company, PaceMate has raised $8 million, employs 50-200 people, and demonstrates strong growth through partnerships like AliveCor and investments from Lead Edge Capital in 2023.[1][2][7]
Founded in 2015 in Bradenton, Florida (now headquartered in Tampa/Sarasota area), PaceMate was established by Ciprian Bordea, Jason Hale, Tripp Higgins, Kevin R. Campbell, and Noemi Ray.[1][4] The founders brought deep expertise in cardiac care and data management, emerging from a need to centralize fragmented cardiac device data that clinicians struggled to handle across disparate sources.[3][4][6] Early traction came from developing PaceMateLIVE as a comprehensive platform for remote monitoring, gaining recognition for reducing alert burdens and integrating with major EHRs, which propelled its evolution into a leader serving major health systems like Duke Health and Sentara Healthcare.[3][4][5]
PaceMate rides the wave of digital health transformation in cardiology, addressing the explosion of remote monitoring data from wearables, implants, and AI-driven devices amid rising chronic heart disease prevalence.[3][4][6] Timing is ideal with post-pandemic telehealth adoption, regulatory pushes for interoperability (e.g., via EHR integrations), and value-based care models favoring outcome-driven platforms that boost reimbursements.[1][3][5] Market forces like aging populations and clinician burnout from data overload favor PaceMate's end-to-end solution, which influences the ecosystem by pioneering collaborations (e.g., AliveCor for ECG triage) and enabling scaled care in IDNs/academic systems, setting standards for AI-enhanced cardiac management.[2][3][4]
PaceMate is poised for accelerated growth through AI integration, expanding PaceMateLIVE to automate triage, predict risks, and support preventive care using its vast dataset—potentially capturing more market share in the $10B+ remote monitoring space.[4] Trends like AI in population health, wearable proliferation, and regulatory data standards will amplify its edge, with recent funding fueling partnerships and enterprise adoption.[2][7] Its influence may evolve from niche cardiac tool to foundational platform across cardiovascular care continuums, consistently delivering on its promise to "never miss a beat" by prioritizing patients in a data-saturated era.[6]
Pace mate has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series A in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $8.0M Series A | Ballast Point Ventures |